Latest filings (excl ownership)
15-12B
Securities registration termination
30 Nov 20
EFFECT
Notice of effectiveness
23 Nov 20
EFFECT
Notice of effectiveness
23 Nov 20
25-NSE
Exchange delisting
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
POS AM
Prospectus update (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Nov 20
8-K
Liquidia Closes Acquisition of RareGen
18 Nov 20
425
Business combination disclosure
16 Nov 20
8-K
Liquidia Announces Results of Special Meeting of Stockholders
16 Nov 20
425
Business combination disclosure
9 Nov 20
8-K
Liquidia Reports Third Quarter 2020 Financial Results and Provides Corporate Update
9 Nov 20
10-Q
2020 Q3
Quarterly report
6 Nov 20
DEFA14A
Additional proxy soliciting materials
5 Nov 20
DEFA14A
Additional proxy soliciting materials
2 Nov 20
8-K
Liquidia Reschedules Special Meeting of Stockholders and Reaffirms Recommendation to Approve Proposed Acquisition of RareGen, LLC
2 Nov 20
DEFA14A
Additional proxy soliciting materials
19 Oct 20
8-K
Liquidia Announces Postponement of Special Meeting of Stockholders
19 Oct 20
8-K
Liquidia Provides Update on U.S. Patent Trial and Appeal Board Decision on Inter Partes Review of Two United Therapeutics’ Tyvaso® Patents
14 Oct 20
DEFA14A
Additional proxy soliciting materials
8 Oct 20
DEFA14A
Additional proxy soliciting materials
18 Sep 20
425
Business combination disclosure
18 Sep 20
DEFA14A
Additional proxy soliciting materials
17 Sep 20
425
Business combination disclosure
17 Sep 20
DEFM14A
Proxy related to merger
17 Sep 20
DEFA14A
Additional proxy soliciting materials
20 Aug 20
425
Business combination disclosure
20 Aug 20
8-K
Liquidia Announces Chief Financial Officer Transition
20 Aug 20
10-Q
2020 Q2
Quarterly report
10 Aug 20
DEFA14A
Additional proxy soliciting materials
10 Aug 20
425
Business combination disclosure
10 Aug 20
8-K
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
10 Aug 20
8-K
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
24 Jul 20
8-K
Liquidia Announces Proposed Offering of Common Stock
2 Jul 20
424B5
Prospectus supplement for primary offering
30 Jun 20
424B5
Prospectus supplement for primary offering
29 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Jun 20
Latest ownership filings
SC 13G/A
ArrowMark Colorado Holdings LLC
16 Feb 21
4
FREDRIC N ESHELMAN
27 Nov 20
4
FREDRIC N ESHELMAN
25 Nov 20
4
FREDRIC N ESHELMAN
24 Nov 20
4
FREDRIC N ESHELMAN
20 Nov 20
144
Notice of proposed sale of securities
20 Nov 20
3
Steven Bariahtaris
21 Aug 20
SC 13D/A
New Enterprise Associates 12, Limited Partnership
7 Jul 20
4
FREDRIC N ESHELMAN
2 Jul 20
4
Stephen M Bloch
23 Jun 20
4
Katherine Rielly-Gauvin
23 Jun 20
4
SETH RUDNICK
23 Jun 20
4
RALPH SNYDERMAN
23 Jun 20
4
Arthur S Kirsch
23 Jun 20
4
RAMAN SINGH
23 Jun 20
4
Joanna Horobin
23 Jun 20
4
Benjamin Maynor
28 May 20
4
Tushar Shah
19 May 20
3
Tushar Shah
19 May 20
4
Benjamin Maynor
16 Apr 20
4
FREDRIC N ESHELMAN
7 Apr 20
4
FREDRIC N ESHELMAN
3 Apr 20
4
FREDRIC N ESHELMAN
1 Apr 20
4
Florina Krawchick
20 Mar 20
4
Robert F Roscigno
20 Mar 20
4
Robert A Lippe
20 Mar 20
4
Neal Franklin Fowler
20 Mar 20
4
Richard D Katz
20 Mar 20
4
Jeri Thomas
20 Mar 20
4
Benjamin Maynor
20 Mar 20
SC 13G
Liquidia Technologies Inc
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Liquidia Technologies Inc
12 Feb 20
SC 13G/A
Liquidia Technologies Inc
6 Feb 20
SC 13G/A
Beneficial ownership report (amended)
6 Feb 20
4
Stephen M Bloch
10 Jan 20
4
Change in insider ownership
10 Jan 20
SC 13G
Liquidia Technologies Inc
7 Jan 20
3
FREDRIC N ESHELMAN
6 Jan 20
4
Katherine Rielly-Gauvin
1 Nov 19